MedTrace Logo

Hydroxychloroquine in Untreated B-CLL Patients

NCT00771056 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-08-22

Study results available
· View outcomes & findings →

Summary

Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine 400mg po daily for up to one year. They will be monitored for disease status as well as adverse reactions after two weeks and then every 4 weeks. Ophthalmologic exams is required at baseline and every 6 months or sooner if the patient develops any visual disturbances.

Conditions

  • B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

Hydroxychloroquine

400mg by mouth daily x 1 year

Sponsors & Collaborators

  • Northwell Health

    lead OTHER

Principal Investigators

  • Kanti R Rai, MD · NSLIJ

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771056 on ClinicalTrials.gov